Skip to search formSkip to main contentSkip to account menu

mTOR Inhibitors [MoA]

Known as: Mammalian Target of Rapamycin Inhibitors, mTOR Inhibitors 
National Institutes of Health

Related topics

Related topics

2 relations
SirolimusmTOR Inhibitor

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
mTOR inhibitors in cancer therapy
The mammalian target of rapamycin, mTOR, plays key roles in cell growth and proliferation, acting at the catalytic subunit of two… 
Review
2016
Review
2016
Targeting angiogenesis in endometrial cancer - new agents for tailored treatments
Introduction: Endometrial carcinoma represents the most frequent gynecologic tumor in developed countries. The majority of women… 
2016
2016
Muscle wasting associated with the long-term use of mTOR inhibitors.
Some targeted therapies alter muscle mass due to interference with pathways of muscle metabolism. The effects of mammalian target… 
Highly Cited
2016
Highly Cited
2016
Experience with belatacept rescue therapy in kidney transplant recipients
In kidney transplant recipients with chronic graft dysfunction, long‐term immunosuppression with calcineurin inhibitors (CNIs) or… 
Review
2015
Review
2015
Lymphatic disorders after renal transplantation: new insights for an old complication
In renal transplanted patients, lymphoceles and lymphorrhea are well-known lymphatic complications. Surgical damage of the… 
Review
2014
Review
2014
Drug interactions with solid tumour-targeted therapies.
Highly Cited
2014
Highly Cited
2014
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
BACKGROUND The clinical trials that reported benefit of the rapalogs temsirolimus and everolimus in advanced renal cell carcinoma… 
Review
2013
Review
2013
Differentiating mTOR inhibitors in renal cell carcinoma.
Review
2012
Review
2012
Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.
BACKGROUND Oral adverse events (OAEs) associated with multitargeted tyrosine kinase inhibitors (TKIs) and mammalian target of… 
Highly Cited
2007
Highly Cited
2007
Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling.
Understanding the pathogenesis of leukemia in the context of lymphopoiesis may reveal novel therapeutic targets. Previously, we… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)